China insurance Report Interpretation

Overview

This sector review examines 2Q26 solvency, reserve disclosure, liquidity, asset allocation and regulatory developments for Chinese insurers. J.P. Morgan concludes that major insurers' capital positions remain sound enough to support stronger dividends, while product-mix changes and tighter ALM discipline should improve longer-term solvency management.

Core views

Chinese life and non-life insurers recorded mixed quarter-on-quarter solvency movements in 2Q26. Strong earnings growth and investment-book valuation gains expanded available capital, with core capital up 5% q/q for major life insurers and 1% q/q for major non-life insurers. Required capital also increased, however: life peers' requirement rose 4.8% q/q as robust life sales and higher equity allocations lifted insurance- and market-risk charges, while non-life peers' required capital rose 0.1% q/q. Consequently, life insurers' solvency ratios increased 0.3 percentage points q/q, while non-life insurers improved 2.1 percentage points year on year. J.P. Morgan emphasizes that major insurers remain above 120%, comfortably exceeding the 50% core-solvency minimum, although companies expect a marginal decline in 3Q26 as business growth continues. The report considers the sector's higher interim dividends sustainable. Major SOE insurers raised interim DPS by more than 40%, including China Life's 50.4% increase to RMB0.358 and PICC Group's 46.7% increase to RMB0.11. The institution views these payouts as supported by capital strength and as evidence that prospective pressure from C-ROSS II Phase 3 may be less significant than feared. It also notes favorable 1H26 underwriting outcomes in non-life insurance: combined ratios were 94.0% for PICC P&C, 95.0% for CPIC Property and 95.1% for Ping An P&C, leaving scope for further solvency-capital improvement. A central structural theme is the transition in life products and asset-liability management. Insurers are shifting toward participating policies with lower minimum guarantees of 1.25%-1.75%, while legacy 3.5% non-participating policies mature. J.P. Morgan expects this to reduce blended funding costs and make required-capital management and liability-driven investment more manageable. The shift is particularly important because the move to fair-value bond valuation under the solvency balance sheet had supported capital while long-end yields declined, but now creates downward solvency pressure as yields recover. The report expects insurers to focus more on duration matching between interest-bearing liabilities and assets, and potentially on reinsurance and derivatives where their costs are economically attractive. Equity exposure increased modestly. Major life insurers' equity-related market risk rose 6% q/q and equity-price-risk capital charges rose 7% q/q, implying more active allocation than in 2025. Market risk remains the largest capital charge, representing over 80% of required capital for life insurers and over 40% for non-life insurers. Insurers have added high-dividend stocks, largely classified as FVOCI, to support dividend income and reduce earnings volatility. J.P. Morgan nevertheless expects equity-allocation growth to remain measured through year-end as lower-guarantee products, policy run-off and higher long-end bond yields reduce the need for an aggressive equity push. It does not expect a single CXMT-related investment gain to materially alter insurers' earnings because these holdings are generally held in insurance funds and participating-policy profit sharing limits the direct bottom-line effect. The report sees regulatory changes as relatively favorable for large insurers. Revised NFRA ALM rules, published on 21 August 2026 and effective from January 2027 with a three-year transition period, strengthen governance, restrict riskier product launches and introduce additional metrics. J.P. Morgan believes scale, compliance capability and more flexible liability structures should advantage major insurers, while smaller and medium-sized firms may face heavier compliance and capital burdens that could support large insurers' market-share gains. The report also notes stronger disclosure of risk appetite, asset allocation and AI-driven risk controls. On reserves, residual-margin disclosure resumed in 1Q26 after its suspension since December 2022. The report welcomes the quarterly format because it improves tracking of reserve-block development. All four examined insurers showed resilient residual-margin recovery versus March 2026. At June 2026, residual margin was 14% above CSM for China Life, 10% above for Ping An Life, 4% above for CPIC Life and 19% above for New China Life; versus December 2022, residual margin was up 13%, down 9%, up 11% and up 7%, respectively. J.P. Morgan notes that CSM and residual margin are not directly comparable because CSM dynamically rolls forward discounted future cash flows and absorbs some variances that residual margin sends directly to earnings. Liquidity and qualitative capital indicators remain broadly manageable. Base-scenario liquidity coverage ratios within three and 12 months increased by 2 percentage points and 1 percentage point q/q, respectively, at the sector level. Ping An Life had the largest coverage ratio among the major life insurers and PICC Life the smallest, but the report does not see significant liquidity risk for major insurers because their capital bases remain solid. Most insurers had SARMRA scores above 80, while all major listed insurers covered had IRR ratings of BB or better; five—China Life, CPIC Life, Ping An Life, Ping An Property and AIA China—held AA ratings in 1Q26. J.P. Morgan will track subsequent solvency reports for rating changes, disclosure consistency, investment yields and funding-cost trends. In valuation terms, the report identifies Ping An-H and China Life-H as top picks, citing 5x FY27E P/E and dividend yields of 7% and 4%, respectively. The comparison table shows Ping An-H rated OW with a HK$98.0 December 2027 target price, versus HK$56.8 on 1 September 2026 and 73% indicated upside; China Life-H is OW with a HK$40.0 target price, versus HK$30.2 and 33% indicated upside.

Analysis framework

J.P. Morgan compares insurers' quarterly C-ROSS II solvency reports, interim and annual financial reports, reserve disclosures, liquidity ratios, underwriting results and asset-allocation data. It assesses how earnings, valuation movements, business growth, product guarantees, interest rates and regulation affect capital adequacy, dividends and relative sector positioning.

Methodology notes

• Financial-sector metricsSolvency analysis

  C-ROSS II core and comprehensive solvency ratios

  The report evaluates capital strength by comparing core capital, and core plus supplementary capital, with minimum capital requirements under China's solvency framework.

• Industry AnalysisSupply-demand framework

  Life-product mix and liability funding costs

  The report links lower guaranteed rates and the run-off of legacy policies to lower funding costs and more manageable capital and asset-liability management.

• Financial-sector metricsNet Interest Margin (NIM) Analysis

  Investment-yield coverage versus liability funding costs

  The report tracks net and comprehensive investment yields against liability funding costs to assess insurers' capacity to support policy obligations.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Ping An Insurance Group - H (2318.HK)

  Top pick; J.P. Morgan links its attractive valuation and yield to sector capital and dividend resilience.

  Strengths

  5x FY27E P/E, 7% yield, OW rating and HK$98.0 target price.

  Comparison

  73% indicated upside from HK$56.8 as of 1 September 2026.

  Risks

  Solvency volatility remains sensitive to interest rates and market-risk charges.

• China Life Insurance - H (2628.HK)

  Top pick; viewed as supported by capital strength and higher payout capacity.

  Strengths

  5x FY27E P/E, 4% yield, OW rating and HK$40.0 target price.

  Comparison

  33% indicated upside from HK$30.2 as of 1 September 2026.

  Risks

  Solvency ratios may decline marginally with continuing business growth and higher required capital.

• China Pacific Insurance Group - H (2601.HK)

  Covered comparable in the China insurance valuation table.

  Strengths

  OW rating and HK$43.0 target price.

  Comparison

  39% indicated upside from HK$30.9.

• New China Life Insurance - H (1336.HK)

  Covered comparable in the China insurance valuation table.

  Strengths

  Residual margin at June 2026 was 19% above CSM.

  Weaknesses

  Neutral rating and HK$46.0 target price below HK$48.3 current price.

  Comparison

  -5% indicated downside.

• PICC Group - H (1339.HK)

  Covered comparable; its CXMT-related investment gain was discussed.

  Strengths

  Interim DPS increased 46.7% year on year to RMB0.11.

  Weaknesses

  J.P. Morgan does not expect a single stock investment to materially change bottom-line earnings.

  Comparison

  Neutral rating; HK$6.0 target price equals HK$6.0 current price.

  Risks

  Potential earnings impact from CXMT-related valuation is limited by insurance-fund ownership and participating-policy profit sharing.

Key data

• Major life insurers' core-capital growth5% q/qSupported by earnings growth and investment-book valuation gains in 2Q26.
• Major life insurers' required-capital growth4.8% q/qDriven by strong life sales and higher equity allocations.
• Minimum core solvency ratio50%Major insurers' ratios remained above 120%.
• China Life interim DPSRMB0.358, +50.4% YoY2026 interim dividend.
• PICC Group interim DPSRMB0.11, +46.7% YoY2026 interim dividend.
• PICC P&C 1H26 combined ratio94.0%Improved 0.8 percentage points year on year.
• Ping An-H valuation5x FY27E P/E; 7% yieldIdentified as a top pick.
• China Life-H valuation5x FY27E P/E; 4% yieldIdentified as a top pick.

Impact & implications

J.P. Morgan believes healthy capital buffers support higher shareholder payouts and reduce concern about impending C-ROSS II pressure. It expects large insurers to be relatively advantaged by stricter ALM rules and sees lower product guarantees, better liability matching and measured equity allocation as supporting more stable capital management.

Risks

• Interest-rate recovery can create downward pressure on life-insurer solvency ratios under fair-value bond valuation.
• Higher life sales and equity allocations raise insurance- and market-risk capital charges.
• Smaller and medium-sized insurers may face greater compliance and capital burdens under revised ALM rules.
• Disclosure formats for newly added residual-margin and operating metrics are not yet fully standardised across the sector.

What to watch

• 3Q26 solvency-ratio projections and the effect of continued business growth on capital requirements.
• Implementation of revised NFRA ALM rules from January 2027 and the three-year transition period.
• The pace of product migration to lower-guarantee participating policies and maturity of legacy 3.5% policies.
• Long-end bond-yield movements, investment yields and blended funding-cost trends.
• Future SARMRA and IRR updates in quarterly solvency reports, including potential scoring updates for large insurers.
• Consistency and comparability of expanded public disclosures.